New trial for children’s malaria vaccine
Children under the age of five stand to benefit from a new malaria vaccine which is due to go into clinical trial in The Gambia this month, once children for the trial have been screened.
The trial is the first concrete step in a new partnership between the Malaria Vaccine Initiative (a programme of the United States-based non-profit organisation, Programme for Appropriate Technology in Health) and GlaxoSmithKline Biologicals.
Children under the age of five and pregnant women are the most vulnerable to malaria. Most of the one million people who die each year are African children under the age of five.
About 90 children between the ages of six to eleven will be involved in the first phase of the trial which will test the safety and immune response of the “RTS, S” vaccine. If the results are successful, two subsequent trials will test the vaccine in children between the ages of one to five.
Resarchers have safely tested the vaccine among adult volunteers in the United States, Belgium, Kenya and The Gambia. To date no malaria vaccines have ever been tested and found successful in children..
In South Africa, malaria has shown a steady increase since the mid-1980s, with a dramatic rise since 1996. District and sub-district analysis by the Department of Health and the Medical Research Council also point to the spread of the disease into previous lower risk areas.
It is estimated that worldwide, about 300 to 500 million people are currently infected by malaria and another 2,3 billion are at risk of the disease.
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
New trial for children’s malaria vaccine
by Health-e News, Health-e News
May 24, 2001